arsenic trioxide has been researched along with Adrenal Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, LC; Bironaite, D; Venalis, A; Westberg, JA | 1 |
| Carrasquillo, JA; Cheung, NK; Kramer, K; Kushner, BH; Larson, SM; Modak, S; Pandit-Taskar, N; Zanzonico, P | 1 |
1 trial(s) available for arsenic trioxide and Adrenal Cancer
| Article | Year |
|---|---|
Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adult; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Male; Neuroblastoma; Oxides; Paraganglioma; Pheochromocytoma; Radiation-Sensitizing Agents; Radiopharmaceuticals; Survival Analysis; Treatment Outcome | 2016 |
1 other study(ies) available for arsenic trioxide and Adrenal Cancer
| Article | Year |
|---|---|
A variety of mild stresses upregulate stanniocalcin-1 (STC-1) and induce mitohormesis in neural crest-derived cells.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Flow Cytometry; Glycoproteins; Hormesis; Humans; Membrane Potential, Mitochondrial; Mitochondria; Neuroblastoma; Oxides; Phorbol Esters; Reactive Oxygen Species; Starvation; Stress, Physiological; Time Factors; Up-Regulation | 2013 |